Neil Cashman, the Chief Scientific Officer at ProMIS Neurosciences Inc., recently acquired 10,000 shares of the company at a price of $3.86 each. This transaction, reported on November 3, 2026, reflects Cashman's confidence in the company's future and its ongoing efforts in the pharmaceutical preparations sector.

Background

ProMIS Neurosciences Inc. is a company focused on developing innovative therapies for neurodegenerative diseases. The firm is classified under the Pharmaceutical Preparations industry. Its recent filings include a Form 4 dated November 3, 2026, detailing Cashman's acquisition of shares. The company operates from Toronto, Ontario, Canada.

What the Filing Says

According to the SEC filing, Cashman acquired 10,000 common shares on November 2, 2026. Following this transaction, he now owns a total of 14,532 shares. The filing states, "transaction price per share: $3.86," indicating the market value at the time of purchase.

Impact

This acquisition may influence investor sentiment regarding ProMIS Neurosciences, particularly as insider buying often signals confidence in a company's prospects. Cashman’s role as both a director and officer may further bolster trust in the company's strategic direction.

What's Next

The filing does not say what happens next.

Ownership Details

Following the acquisition, Neil Cashman holds a total of 14,532 shares of ProMIS Neurosciences Inc. The filing also indicates that he has indirect ownership of an additional 4,122 shares through Research Capital Corporation and 664 shares owned by his spouse, further demonstrating a significant personal investment in the company.

Transaction Specifics

The transaction was coded as an acquisition (indicated by the code 'A') and was executed on November 2, 2026. The shares acquired were common shares, which are typically the most common type of equity ownership in a company.

Company Background

ProMIS Neurosciences Inc. is incorporated in Ontario, Canada, and operates under the standard industrial classification of Pharmaceutical Preparations. The company was formerly known as Amorfix Life Sciences Ltd., with the name change taking effect on August 31, 2006.

Regulatory Information

This filing was submitted under the SEC Act of 1934, and it is categorized as a Form 4, which is used to report transactions made by insiders of the company. The filing reflects the company's compliance with SEC regulations regarding insider trading.